Pathophysiology of PTH-related Protein (1-36) in Humans
Pathophysiology of PTH-related Protein (1-36) in Humans
批准号:
8068432
负责人:
ANDREW F. STEWART
金额:
$3.41万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2010-09-30
关键词:
Adverse effectsAgeAgingAnabolic AgentsAnimalsAuthorization documentationBiochemicalBiologicalBiomechanicsBone DensityChemicalsChildClinicalCongressesDataData AggregationDefectDevelopmentDocumentationDoseFDA approvedFaceFamilyFractureFunctional disorderFundingFunding ApplicantGlucocorticoidsGoalsGoldGrantHandHeadHumanHypercalcemiaImmunoassayInferiorInstitutionInterventionKnock-outLeadMethionineMineralsMissionMolecularMorbidity - disease rateMusMuscle CrampNational Institute of Diabetes and Digestive and Kidney DiseasesNauseaOsteoblastsOsteoporosisOutcomePTH genePainParathyroid HormonesPatientsPharmacologic SubstancePhysiologicalPhysiologyPostdoctoral FellowPostmenopausal OsteoporosisPostmenopauseProgress ReportsPropertyProtein BindingPublishingRandomized Controlled Clinical TrialsRattusReaderRefrigerationReportingResearchResourcesRoleSafetySeriesSiteSkeletal DevelopmentStagingSyndromeTherapeuticTherapeutic AgentsTimeTranslational ResearchUnited States National Institutes of HealthVertebral columnWomanWorkbasebonecohortdisabilityhuman PTH proteinhuman datamenmineralizationmortalitynoveloxidationparathyroid hormone (1-34)parathyroid hormone-related peptide (1-36)parathyroid hormone-related proteinposterspre-clinicalpreclinical studyprogramspublic health relevancereceptorskeletalyoung adult
中文摘要
描述(由申请人提供):这是R-01DK51081的竞争性延续申请。过去对甲状旁腺激素相关蛋白(PTHrP)在人体生理中的作用进行了探讨。在最近的周期中,它还专注于探索PTHrP作为治疗骨质疏松症的合成代谢骨骼剂的治疗潜力。先前版本的数据表明,PTHrP至少与目前用于骨质疏松症合成代谢治疗的金标准:甲状旁腺激素或PTH一样有效(1-34)。此外,在前一轮融资中,我们已经确定了PTHrP在健康年轻人和绝经后妇女中的完整治疗窗口(1-36):这些研究表明,比以前使用的剂量更高的PTHrP似乎既安全又有效。这些发现表明,高剂量的PTHrP可能比先前的研究更有效。此外,除了潜在的优越疗效外,PTHrP似乎具有优越的安全性和耐受性,在治疗剂量下没有高钙血症、恶心、肌肉痉挛或其他不良反应。最后,与甲状旁腺激素是一种混合合成代谢和分解代谢剂相比,甲状旁腺激素似乎是一种纯合成代谢剂。总的来说,这些研究要求对PTH(1-34)与PTHrP(1-36)治疗绝经后骨质疏松症进行明确的头对头比较试验。这是本研究的单一特定目的:进行PTHrP(1-36)与PTH(1-34)治疗绝经后骨质疏松症的直接、直接比较、随机对照临床试验,同时具有安全性/耐受性和有效性终点。
英文摘要
DESCRIPTION (provided by applicant): This is a competing continuation application of R-01DK51081. In the past, it has explored the human physiology of parathyroid hormone-related protein (PTHrP). In its most recent cycles, it has also focused on exploring the therapeutic potential of PTHrP as an anabolic skeletal agent for the treatment of osteoporosis. Data in the prior versions have demonstrated that PTHrP is at least as efficacious in humans as the current gold standard for the anabolic treatment of osteoporosis: parathyroid hormone or PTH(1-34). In addition, in the prior round of funding, we have defined the complete therapeutic window of PTHrP(1-36) in healthy young adults as well as in postmenopausal women: these studies demonstrate that doses of PTHrP higher than those previously employed appear safe as well as effective. These findings suggest that higher doses of PTHrP may be even more efficacious than those prior studied. Further, in addition to potential superior efficacy, PTHrP appears to have a superior safety and tolerability profile, with no hypercalcemia, nausea, muscle cramps or other adverse effects at therapeutic doses. Finally, in contrast to PTH which is a mixed anabolic and catabolic agent, PTHrP appears to be a pure anabolic agent. Collectively, these studies mandate a definitive head-to-head comparator trial of PTH(1-34) vs. PTHrP(1-36) in the treatment of postmenopausal osteoporosis. This is the single Specific Aim of this study: To perform a direct, head-to-head, direct comparator, randomized, controlled clinical trial of PTHrP(1-36) vs. PTH(1-34) for the treatment of postmenopausal osteoporosis, with both safety/tolerability and efficacy endpoints.
PUBLIC HEALTH RELEVANCE: Osteoporosis is a major cause of fracture, pain, disability, and other morbidities as well as mortality in postmenopausal women, aging men, and patients treated with glucocorticoids. Anti-resorptive therapies are partially effective, and anabolic therapies are even more effective. The current gold standard anabolic agent is PTH(1-34), but its safety and efficacy is limited by nausea, muscle cramps, hypercalcemia and other adverse effects. Reports published from earlier versions of this grant suggest that PTHrP may have superior safety and tolerability, and also may confer efficacy advantages over PTH. The purpose of this project is to directly compare, for the first time, PTH and PTHrP in an efficacy and safety/tolerability study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DREAM Complex Maintenance of Human Beta Cell Quiescence
-
批准号:10427406
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2021
-
负责人:ANDREW F. STEWART
-
依托单位:
DREAM Complex Maintenance of Human Beta Cell Quiescence
-
批准号:10267388
-
项目类别:
-
资助金额:$61.53万
-
财政年份:2021
-
负责人:ANDREW F. STEWART
-
依托单位:
DREAM Complex Maintenance of Human Beta Cell Quiescence
-
批准号:10619645
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2021
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8815293
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8636445
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8583716
-
项目类别:
-
资助金额:$23.23万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8470622
-
项目类别:
-
资助金额:$33.62万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8144434
-
项目类别:
-
资助金额:$87.15万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8636565
-
项目类别:
-
资助金额:$71.16万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8717646
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8316307
-
项目类别:
-
资助金额:$15.99万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8655150
-
项目类别:
-
资助金额:$92.07万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:7993980
-
项目类别:
-
资助金额:$87.15万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
MODELING BONE FORMATION AND 125 VITAMIN D IN HUMORAL HYPERCALCEMIA OF MALIGNANCY
-
批准号:7139533
-
项目类别:
-
资助金额:$29.25万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
MODELING BONE FORMATION & 1,25 VITAMIN D IN HUMORAL HYPERCALCEMIA OF MALIGNANCY
-
批准号:7460757
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
MODELING BONE FORMATION & 1,25 VITAMIN D IN HUMORAL HYPERCALCEMIA OF MALIGNANCY
-
批准号:7260457
-
项目类别:
-
资助金额:$29.56万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
Modeling Bone Formation and 1,25 Vitamin D in Humoral Hypercalcemia of Malignancy
-
批准号:7650170
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
Renal Calcium Handling & 1, 25 Vitamin D Synthesis
-
批准号:6974659
-
项目类别:
-
资助金额:$5.62万
-
财政年份:2004
-
负责人:ANDREW F. STEWART
-
依托单位:
Anabolic Skeletal Agents for Osteoporosis
-
批准号:6754239
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2004
-
负责人:ANDREW F. STEWART
-
依托单位:
Islet Allograft Gene Therapy for Primate Diabetes
-
批准号:6803476
-
项目类别:
-
资助金额:$59.31万
-
财政年份:2003
-
负责人:ANDREW F. STEWART
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: